Amedisys (NASDAQ:AMED) PT Lowered to $175.00

Amedisys (NASDAQ:AMEDGet Rating) had its price target decreased by investment analysts at Truist Financial from $200.00 to $175.00 in a research note issued on Tuesday, The Fly reports. Truist Financial’s price objective indicates a potential upside of 44.19% from the stock’s previous close.

Several other analysts have also issued reports on AMED. Stephens reduced their target price on Amedisys from $155.00 to $125.00 in a report on Tuesday. UBS Group raised Amedisys from a “sell” rating to a “neutral” rating and increased their target price for the stock from $152.00 to $168.00 in a report on Tuesday, March 1st. Deutsche Bank Aktiengesellschaft reduced their target price on Amedisys from $230.00 to $210.00 in a report on Friday, April 29th. Credit Suisse Group reduced their target price on Amedisys from $200.00 to $195.00 and set an “outperform” rating on the stock in a report on Friday, February 25th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $200.00 price objective on shares of Amedisys in a research note on Thursday, April 7th. Six equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $184.13.

Shares of NASDAQ AMED opened at $121.37 on Tuesday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.03 and a quick ratio of 1.03. The stock’s fifty day moving average price is $125.11 and its two-hundred day moving average price is $143.02. Amedisys has a one year low of $109.30 and a one year high of $276.21. The firm has a market cap of $3.95 billion, a price-to-earnings ratio of 20.89, a P/E/G ratio of 2.37 and a beta of 0.89.

Amedisys (NASDAQ:AMEDGet Rating) last issued its quarterly earnings data on Wednesday, April 27th. The health services provider reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $1.11 by $0.12. Amedisys had a return on equity of 19.37% and a net margin of 8.59%. The firm had revenue of $545.26 million for the quarter, compared to analyst estimates of $557.81 million. During the same period in the prior year, the firm posted $1.54 EPS. On average, equities analysts anticipate that Amedisys will post 5.29 earnings per share for the current fiscal year.

In other Amedisys news, insider David L. Kemmerly sold 2,500 shares of the firm’s stock in a transaction that occurred on Tuesday, March 29th. The stock was sold at an average price of $177.31, for a total value of $443,275.00. Following the completion of the sale, the insider now owns 16,336 shares of the company’s stock, valued at $2,896,536.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.10% of the company’s stock.

Large investors have recently made changes to their positions in the stock. New York State Teachers Retirement System boosted its position in shares of Amedisys by 7.3% during the fourth quarter. New York State Teachers Retirement System now owns 44,390 shares of the health services provider’s stock valued at $7,186,000 after buying an additional 3,015 shares during the last quarter. TD Asset Management Inc. boosted its position in shares of Amedisys by 113.0% during the fourth quarter. TD Asset Management Inc. now owns 25,252 shares of the health services provider’s stock valued at $4,088,000 after buying an additional 13,394 shares during the last quarter. First Trust Advisors LP boosted its position in shares of Amedisys by 235.6% during the fourth quarter. First Trust Advisors LP now owns 151,640 shares of the health services provider’s stock valued at $24,547,000 after buying an additional 106,453 shares during the last quarter. Advisor Partners LLC purchased a new position in shares of Amedisys during the fourth quarter valued at approximately $215,000. Finally, Riverbridge Partners LLC boosted its position in shares of Amedisys by 57.0% during the fourth quarter. Riverbridge Partners LLC now owns 1,588,750 shares of the health services provider’s stock valued at $257,187,000 after buying an additional 576,633 shares during the last quarter. 90.47% of the stock is currently owned by institutional investors.

About Amedisys (Get Rating)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Further Reading

The Fly logo

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.